NASA doled out funding to 12 startups — and one from Houston makes the cut. Photo courtesy of re:3D

Houston-based re:3D Inc was recently one of 12 innovative companies from around the country to be granted Phase II awards from a NASA small business initiative, the space giant announced earlier this week.

The grants of up to $850,000 are awarded to early-stage, high-risk technology concepts that could be commercialized for use in space and on Earth as part of NASA's SBIR Ignite pilot, which is part of NASA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.

The program was launched to support emerging companies "whose end customers may not be only NASA but are still creating technology that NASA cares about,” Jason L. Kessler, program executive for the NASA SBIR/STTR program, says in a previous statement. And it aims to attract companies that have not yet worked with NASA.

The concepts from the cohort have applications in climate resilience, low-cost solar cells and active debris remediation. Re:3D Inc.'s project looks to develop a recycling system that uses a 3D printer to turn thermoplastic waste generated in orbit into functional and useful objects, according to the project's proposal.

SBIR Ignite made its inaugural Phase I awards in 2022, granting about $2 million in total to the 12 companies, including re:3D Inc. The Phase II grants are intended to help the companies create their prototypes.

“We are proud that all 12 of the small businesses are continuing with our program and persevering through the tough realities of early-stage research and development,” Kessler said in a statement made this month. "These awards foster a unique range of technologies that we hope will have positive impacts on the lives of everyday Americans in the future."

Re3D Inc. is the only company from Texas in the cohort. The other 11 awarded companies and their projects include:

  • Ampaire Inc.: High Efficiency Powertrain for Hybrid Aircraft
  • Canopy Aerospace Inc.: Reusable Heatshields through Additive Manufacturing
  • Cecilia Energy: Catalytic Conversion of Waste Plastic to Hydrogen
  • Crystal Sonic Inc.: Reducing Cost of Space Photovoltaics via Sound-Assisted Substrate Reuse
  • H3X Technologies Inc.: HPDM-30 – A 10 kW/kg Integrated Motor Drive for UAV and Aircraft Electric Propulsion
  • Outpost Technologies Corporation: Outpost Cargo Ferry: A Rapid Cargo Downmass Vehicle
  • Solestial, Inc.: Next Generation Silicon Based Solar Arrays for Space Stations and Other Permanent Space Infrastructure
  • StormImpact Inc.: Optimizing vegetation management to improve the resilience of the electrical power system to extreme weather
  • Terrafuse, Inc.: Wildfire Mitigation through Explainable Risk Predictions
  • Trans Astronautica Corporation: Mini Bee Capture Bag for Active Debris Remediation
  • Turion Space Corp.: Low-Cost CubeSat for Active Removal of Sizable Space Debris Utilizing a Mothership Architecture

Re:3D Inc. was founded in 2013 by NASA contractors Samantha Snabes and Matthew Fiedler and is based in Clear Lake. It's known for its GigaBot 3D printer, which uses recycled materials to create larger devices.

Since its founding it's been named to numerous accelerators and has earned national recognition, like the Tibbetts Award from the U.S. Small Business Administration, which honors small businesses that are at the forefront of technology. It was selected by the SBA to participate in its inaugural America’s Seed Fund Startup Expo last year.

Co-founder Snabes spoke on the Houston Innovators Podcast in 2020. Click here to listen to the full, in-depth interview.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.